Novel agents for relapsed and/or refractory multiple myeloma.
The introduction of novel agents, such as thalidomide, bortezomib, and lenalidomide, has altered the landscape of therapeutic options for multiple myeloma by offering new mechanisms for targeting this disease. Combinations of these agents, with each other and/or traditional chemotherapeutics, have vastly increased the treatment options for patients both frontline, and at relapse, providing higher response rates, and importantly, increasing median overall survival. In this review, we will discuss the use of these novel agents and their combinations in patients with relapsed and/or refractory multiple myeloma.
Thomas
Sheeba K
SK
Division of Cancer Medicine, Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Holcombe Boulevard, Unit 429, Houston, TX 77030-4009, USA. sthomas@mdanderson.org
Richards
Tiffany A
TA
Weber
Donna M
DM
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001897:Boronic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D000069286:Bortezomib; D003907:Dexamethasone / Q000008:administration & dosage; D006801:Humans; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000188:drug therapy*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D011719:Pyrazines / Q000008:administration & dosage / Q000627:therapeutic use*; D012008:Recurrence; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017211:Treatment Failure
D020533:Angiogenesis Inhibitors; D001897:Boronic Acids; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D003907:Dexamethasone; D000077269:Lenalidomide